IUGNF - Imugene sees positive early signals in Phase 1 VAXINIA study

(NewsDirect)

Imugene Ltd (ASX:IMU)(OTCMKTS:IUGNF) CEO Leslie Chong talks Proactive through a clinicaltrial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours)trial evaluating the safety and efficacy of novel cancer-killing virusCF33-hNIS (VAXINIA). Chong says the early positive response data beingseen at the mid-dose level in hard-to-treat bile duct cancer suggeststhat VAXINIA may be a potent anti-cancer drug as IMU interrogateshigher dose levels.

Chong said: “As we near closer to opening and completing thefinal cohorts that were planned at the beginning of the trial, we havean opportunity to expand the trial by enrolling patients in additionalcohorts for the monotherapy dose escalation component.

“This will provide us with a far morerobust data set to analyse and speak to at the conclusion of the MASTstudy, and provide us with a stronger platform as we further theclinical development of CF33 and VAXINIA.”

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.